دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory FailureThe REST Randomized Clinical Trial
James J. McNamee, MB, ChB1,2; Michael A. Gillies, MD3; Nicholas A. Barrett, MB, ChB4; Gavin D. Perkins, MD5,6; William Tunnicliffe, MSc7; Duncan Young, DM8; Andrew Bentley, MD9,10; David A. Harrison, PhD11; Daniel Brodie, MD12,13; Andrew J. Boyle, MB, ChB1,2; Jonathan E. Millar, PhD14; Tamas Szakmany, PhD15,16; Jonathan Bannard-Smith, MB, ChB17,18; Redmond P. Tully, MBBS19; Ashley Agus, PhD20; Clíona McDowell, MSc20; Colette Jackson20; Daniel F. McAuley, MD1,2; for the REST Investigators
doi : 10.1001/jama.2021.13374
JAMA. 2021;326(11):1013-1023
In patients who require mechanical ventilation for acute hypoxemic respiratory failure, further reduction in tidal volumes, compared with conventional low tidal volume ventilation, may improve outcomes.
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill PatientsA Randomized Clinical Trial
Jennie Johnstone, MD, PhD1; Maureen Meade, MD, MSc2; François Lauzier, MD, MSc3; John Marshall, MD1; Erick Duan, MD, MSc2; Joanna Dionne, MD, PhD2; Yaseen M. Arabi, MD4; Diane Heels-Ansdell, MSc2; Lehana Thabane, PhD2; Daphnee Lamarche2; Michael Surette, PhD2; Nicole Zytaruk, RN2; Sangeeta Mehta, MD1; Peter Dodek, MD, MHSc5; Lauralyn McIntyre, MD, MSc6; Shane English, MD, MSc6; Bram Rochwerg, MD, MSc2; Tim Karachi, MD2; William Henderson5; Gordon Wood, MD7; Daniel Ovakim, MD, MSc7; Margaret Herridge, MD, MPH1; John Granton, MD1; M. Elizabeth Wilcox1; Alberto Goffi, MD1; Henry T. Stelfox, MD, PhD8; Daniel Niven, MD, MSc8; John Muscedere, MD9; François Lamontagne, MD, MSc10; Frédérick D’Aragon, MD, MSc10; Charles St.-Arnaud, MD10; Ian Ball, MD, MSc11; Dave Nagpal, MD11; Martin Girard, MD, MSc12; Pierre Aslanian, MD12; Emmanuel Charbonney, MD, PhD12; David Williamson, PhD12; Wendy Sligl, MD, MSc13; Jan Friedrich, MD, MSc1; Neill K. Adhikari, MDCM, MSc1; François Marquis, MD, MA12; Patrick Archambault, MD, MSc3; Kosar Khwaja, MD14; Arnold Kristof, MD, PhD14; James Kutsogiannis, MD13; Ryan Zarychanski, MD, MSc15; Bojan Paunovic, MD15; Brenda Reeve, MD2; François Lellouche, MD, PhD3; Paul Hosek, MD2; Jennifer Tsang, MD2; Alexandra Binnie, MD, DPhil1; Sébastien Trop, MD, PhD12; Osama Loubani, MD16; Richard Hall, MD16; Robert Cirone, MD1; Steve Reynolds, MD5; Paul Lysecki, MD2; Eyal Golan, MD, PhD1; Rodrigo Cartin-Ceba, MD17; Robert Taylor, MD18; Deborah Cook, MD, MSc2; for the Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials Group
doi : 10.1001/jama.2021.13355
JAMA. 2021;326(11):1024-1033
Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported.
Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Among Patients at Low Surgical Risk
Raj R. Makkar, MD1; Sung-Han Yoon, MD1; Tarun Chakravarty, MD1; Samir R. Kapadia, MD2; Amar Krishnaswamy, MD2; Pinak B. Shah, MD3; Tsuyoshi Kaneko, MD3; Eric R. Skipper, MD4; Michael Rinaldi, MD4; Vasilis Babaliaros, MD5; Sreekanth Vemulapalli, MD6; Alfredo Trento, MD1; Wen Cheng, MD1; Susheel Kodali, MD7; Michael J. Mack, MD8; Martin B. Leon, MD7; Vinod H. Thourani, MD9
doi : 10.1001/jama.2021.13346
JAMA. 2021;326(11):1034-1044
There are limited data on outcomes of transcatheter aortic valve replacement (TAVR) for bicuspid aortic stenosis in patients at low surgical risk.
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
Ilies Benotmane, MD1; Gabriela Gautier, MD1; Peggy Perrin, MD1; Jérôme Olagne, MD1; Noëlle Cognard, MD1; Samira Fafi-Kremer, PharmD, PhD2; Sophie Caillard, MD, PhD1
doi : 10.1001/jama.2021.12339
JAMA. 2021;326(11):1063-1065
Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection
Zion Congrave-Wilson, MS1; Yesun Lee, PhD1; Jaycee Jumarang, MD1; Stephanie Perez, BS1; Jeffrey M. Bender, MD2; Jennifer Dien Bard, PhD3; Pia S. Pannaraj, MD, MPH2
doi : 10.1001/jama.2021.13967
JAMA. 2021;326(11):1065-1067
A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational StudiesThe AGReMA Statement
Hopin Lee, PhD1,2; Aidan G. Cashin, PhD3,4; Sarah E. Lamb, DPhil1,5; Sally Hopewell, DPhil1; Stijn Vansteelandt, PhD6,7; Tyler J. VanderWeele, PhD8; David P. MacKinnon, PhD9; Gemma Mansell, PhD10; Gary S. Collins, PhD1,11; Robert M. Golub, MD12,13; James H. McAuley, PhD4,14; and the AGReMA group
doi : 10.1001/jama.2021.14075
JAMA. 2021;326(11):1045-1056
Mediation analyses of randomized trials and observational studies can generate evidence about the mechanisms by which interventions and exposures may influence health outcomes. Publications of mediation analyses are increasing, but the quality of their reporting is suboptimal.
Confronting the Delta Variant of SARS-CoV-2, Summer 2021
Carlos del Rio, MD1,2; Preeti N. Malani, MD, MSJ3,4; Saad B. Omer, MBBS, PhD5
doi : 10.1001/jama.2021.14811
JAMA. 2021;326(11):1001-1002
Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals
Sameer S. Kadri, MD, MS1; Steven Q. Simpson, MD2
doi : 10.1001/jama.2021.13941
JAMA. 2021;326(11):1003-1004
The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health
Rebecca G. Baker, PhD1; Walter J. Koroshetz, MD2; Nora D. Volkow, MD3
doi : 10.1001/jama.2021.13300
JAMA. 2021;326(11):1005-1006
It Is What It Is
Meeta Prasad Kerlin, MD, MSCE1
doi : 10.1001/jama.2021.14917
JAMA. 2021;326(11):1007-1008
Transcatheter Valve Replacement for Bicuspid Aortic Stenosis
Catherine M. Otto, MD1; David E. Newby, MD2
doi : 10.1001/jama.2021.13229
JAMA. 2021;326(11):1009-1010
A Reporting Guideline for Mediation Analyses
Kabir Yadav, MDCM, MS, MSHS1,2,3; Roger J. Lewis, MD, PhD1,2,3,4
doi : 10.1001/jama.2021.15462
JAMA. 2021;326(11):1011-1012
Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy
Benjamin A. Derman, MD1; Andrew M. Davis, MD, MPH2
doi : 10.1001/jama.2021.7458
JAMA. 2021;326(11):1058-1059
Reporting Findings From Mediation Analyses
Phil B. Fontanarosa, MD, MBA1
doi : 10.1001/jama.2021.15786
JAMA. 2021;326(11):1057
Twenty Years After 9/11, Responders Are Still Healing
doi : 10.1001/jama.2021.14010
JAMA. 2021;326(11):995-998
New Treatment Approved for Adults and Children With Pompe Disease
Bridget M. Kuehn, MS
doi : 10.1001/jama.2021.15588
JAMA. 2021;326(11):1000
Lupus Drug Is Approved Despite Previous Clinical Trial Setback
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14964
JAMA. 2021;326(11):1000
“Collaborative Communities” Tackle Device Development Challenges
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.15589
JAMA. 2021;326(11):1000
Increase in Myopia Reported Among Children During COVID-19 Lockdown
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.14475
JAMA. 2021;326(11):999
India Takes Aim at Eliminating Visceral Leishmaniasis
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.15467
JAMA. 2021;326(11):999
US Health System Ranks Last Among High-Income Countries
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.15468
JAMA. 2021;326(11):999
MD-Granting Medical Schools in the United States, 2020-2021
Barbara Barzansky, PhD1; Sylvia I. Etzel1
doi : 10.1001/jama.2021.12944
JAMA. 2021;326(11):1077-1087
Graduate Medical Education, 2020-2021
Sarah E. Brotherton, PhD1; Sylvia I. Etzel1
doi : 10.1001/jama.2021.13501
JAMA. 2021;326(11):1088-1110
Pulmonary Hypertension
Kristin Walter, MD, MS1
doi : 10.1001/jama.2021.11054
JAMA. 2021;326(11):1116
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases
Konstantinos Papamichail, MD, PhD1; Marla C. Dubinsky, MD2; Adam S. Cheifetz, MD1
doi : 10.1001/jama.2021.11477
JAMA. 2021;326(11):1067-1068
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases
Trond Trætteberg Serkland, MD1; Silje Skrede, MD, PhD2; Jon Andsnes Berg, MD1
doi : 10.1001/jama.2021.11471
JAMA. 2021;326(11):1068-1069
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases
Olivier Le Tilly, MS, PharmD1; Gilles Paintaud, PhD, MD1; David Ternant, PhD, PharmD1
doi : 10.1001/jama.2021.11474
JAMA. 2021;326(11):1069
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases—Reply
Silje Watterdal Syversen, MD, PhD1; Nils Bolstad, MD, PhD2; Espen A. Haavardsholm, MD, PhD1
doi : 10.1001/jama.2021.11480
JAMA. 2021;326(11):1069-1070
Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis
Ching-Yi Chen, MD1; Cheng-Yi Wang, MD2; Chih-Cheng Lai, MD3
doi : 10.1001/jama.2021.11810
JAMA. 2021;326(11):1070-1071
Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis—Reply
Fernando J. Martinez, MD, MS1; Kevin J. Anstrom, PhD2; Imre Noth, MD3
doi : 10.1001/jama.2021.11813
JAMA. 2021;326(11):1071-1072
Addition of Nonauthor Collaborator Names of the VICTAS Trial
doi : 10.1001/jama.2021.15080
JAMA. 2021;326(11):1072
